Stockwinners Market Radar for April 19, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:36 EDT Cathie Wood's ARK Investment bought 21K shares of Twilio today

20:00 EDT CSX reaches tentative agreement with union on future wage adjustments - CSX "announced it has reached a tentative agreement with the Sheet Metal, Air, Rail and Transportation Workers, Transportation Division, or SMART-TD, to provide SMART-TD Trainmen and Yardmasters with monthly advance payments on future wage adjustments anticipated in settlement of the 2020 round of national bargaining between rail labor and the Class I railroads. CSX also notified its other labor organization representatives that it intends to reach agreements to provide identical payments to all unionized employees. The tentative agreement with SMART-TD provides that the monthly payments of up to $600 would be made from May 2022 through the end of the year, or until negotiated wage settlement is reached, whichever is earlier. The advance payments would be deducted from any retroactive or future pay increases that may be agreed upon at national bargaining."

18:48 EDT Prologis CEO: We operate in 19 different countries - In an interview on CNBC's Mad Money, Hamid Moghadam said Prologis is a global business and that is a competitive advantage. There is a big runway for growth, he noted, as many markets it operates in are not mature. The company is one of the top producers of solar energy and he expects that to continue as it expands.

18:31 EDT Rio Tinto reports Q1 Pilbara iron ore production 71.7 Mt, down 6% - Reports Q1 Bauxite production 13.6 Mt, flat year-over-year. Reports Q1 aluminum production 736 kt, down 8%. Reports Q1 mined copper production 125 kt, up 4%. Rio Tinto Chief Executive Jakob Stausholm, said: "We made notable progress during the quarter with the commencement of underground mining at Oyu Tolgoi following a comprehensive agreement reached with the Government of Mongolia, completed the acquisition of the Rincon lithium project in Argentina, and signed a framework agreement at the Simandou iron ore project in Guinea. These projects are all aligned with our strategy of growing in materials essential to a decarbonising world. Production in the first quarter was challenging as expected, re-emphasising a need to lift our operational performance. We launched seven more deployments of the Rio Tinto Safe Production System, building on the achievements from the previous rollouts. As we ramp up Gudai-Darri, our iron ore business will have greater production capacity and be better placed to produce additional tonnes of Pilbara Blend in the second half. We released an independent report on our workplace culture and are implementing all 26 recommendations to make positive and lasting changes. We also announced an agreement with the Yinhawangka Aboriginal Corporation on a new co-designed management plan to ensure the protection of significant social and cultural heritage values. These actions will ensure we continue to deliver attractive returns to shareholders, as we invest in sustaining and growing our portfolio, be a partner and employer of choice and progress our ambition to achieve net-zero carbon emissions."

18:24 EDT DOJ to appeal ruling that lifted COVID mask mandate on travel - The U.S. Department of Justice released the following statement on Health Freedom Defense Fund Inc., et. al. v. Biden, et. al. from spokesman Anthony Coley: "The Department of Justice and the Centers for Disease Control and Prevention (CDC) disagree with the district court's decision and will appeal, subject to CDC's conclusion that the order remains necessary for public health. The Department continues to believe that the order requiring masking in the transportation corridor is a valid exercise of the authority Congress has given CDC to protect the public health. That is an important authority the Department will continue to work to preserve. On April 13, 2022, before the district court's decision, CDC explained that the order would remain in effect while it assessed current public health conditions, and that the Transportation Security Administration would extend its directive implementing the order until May 3 to facilitate CDC's assessment. If CDC concludes that a mandatory order remains necessary for the public's health after that assessment, the Department of Justice will appeal the district court's decision." Publicly traded companies in the space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL).

18:17 EDT Netflix says Q2 typically a softer quarter seasonally - Says will look to deploy methods of charging for sharing globally. Says Q2 typically a softer seasonal quarter. Says feeling heightened level of competition.

18:10 EDT Netflix to test ways to charge for account sharing this year - Says elevated churn limited Q1 growth. Says looking to "monetize" account sharing. Says core addressable market "still there." Says will test ways to charge for sharing this year. Comments taken from Q1 earnings conference call.

17:17 EDT U.S. Silica to raise prices on industrial and specialty products by up to 25% - U.S. Silica said that "part of its Industrial and Specialty Products business will increase prices for most of its non-contracted diatomaceous earth, perlite and cellulose products used primarily in food and beverage filtration, renewable diesel, catalysts, paints and coatings, plastics and industrial oil. Price increases will range up to 25%, depending on the product and grade. The price increases are effective for shipments starting May 15, 2022. This increase is driven by ongoing inflationary pressures around raw materials, packaging, labor, logistics and maintenance expenses."

17:16 EDT Lockheed Martin awarded $396.73M Navy contract modification - Lockheed Martin was awarded a $396.73M fixed-price-incentive modification to exercise options under a previously awarded contract for Trident II missile production and deployed systems support. Work is expected to be completed September 30, 2026. FY22 weapon procurement funds in the amount of $396.36M and FY21 weapon procurement funds in the amount of $375,344 will be obligated at time of award, none of which will expire at the end of the current fiscal year. This contract is being awarded to the contractor on a sole source basis under 10 U.S. Code 2304 and was previously synopsized on the Federal Business Opportunities website. Strategic Systems Programs is the contracting activity.

17:04 EDT Turquoise Hill raises FY22 gold production view to 135K-165K ounces - Previous view 115K-165K ounces. Backs FY22 copper production view 110K-150K tonnes.

17:01 EDT Fiserv, Equifax to collaborate on new offerings - Equifax (EFX) and Fiserv (FISV) are partnering to deliver the data-driven insights organizations need to succeed in a digital economy. The companies are collaborating on new offerings that deliver a more holistic picture of businesses and their data and enable financial institutions and businesses of all sizes to embrace the power of real-time data insights. Equifax and Fiserv are targeting late 2022 to deploy joint commercial solutions that leverage new analytics to help strengthen business verification, accelerate account acquisition and enhance risk assessment for small-to-medium sized businesses. The two companies plan to expand innovation efforts into the consumer ecosystem in the future.

16:48 EDT Geospace awarded two contracts worth over $7M for ocean bottom node rental - Geospace announced two contracts together valued at over $7M for the rental of OBX ocean bottom nodes for both deepwater and shallow water marine seismic surveys. The first of the two contracts is with an international marine geophysical services provider who will rent approximately 7,500 OBX-750E seabed ocean bottom wireless seismic data acquisition nodes. These nodes are designed to operate at a maximum depth of 750 meters and are used primarily for shallow offshore waters and transition zones, which include estuaries, marsh wetlands, and freshwater environments, such as rivers and lakes. The second contract is with another international marine geophysical service provider who will rent 1,900 OBX2-90 and OBX2-125 nodes to conduct a seismic survey in the North Sea, which is scheduled to start in the second calendar quarter of 2022. The Geospace OBX2-90 and OBX2-125 will be used in combination with towed streamers for subsurface seismic imaging.

16:43 EDT Stride jumps over 4% to $36.99 after Q3 earnings beat and raised guidance

16:34 EDT Liquidia director Manning acquires 392,156 common shares - In a regulatory filing, Liquidia director Paul Manning disclosed the purchase of 392,156 common shares of the company on April 18 at a price of $5.10 per share.

16:25 EDT Huntsman comments on pending discrimination lawsuit - The company said, "Huntsman Corporation does not typically comment about pending lawsuits. When necessary, however, Huntsman will publicly defend its reputation and the integrity of its employees. Huntsman will also set the record straight when it faces false charges that touch on matters of public interest like racial discrimination. Recently, a law firm released a statement regarding a lawsuit it filed against Huntsman in Los Angeles on behalf of two former employees of its West San Fernando Road facility. The former employees are claiming they faced hostile and discriminatory treatment at that worksite due to their race, national origin, and sex, and that they were wrongfully terminated. These charges are false. Following a thorough investigation, the two plaintiffs were terminated by local management last November for misconduct and unprofessional behavior in the workplace. The investigation revealed that the plaintiffs took multiple unauthorized and extended breaks to meet in private, and, according to one of them, engage in consensual intimate encounters in various locations throughout the facility. The decision to terminate their employment was not racially motivated in any way. Huntsman stands firmly against all forms of discrimination in and outside of the workplace and thoroughly investigates all claims of misconduct or unethical behavior. Claims and concerns can be raised through multiple channels - including an anonymous hotline, none of which these former employees chose to utilize. Huntsman will aggressively defend the case and the integrity of its local workforce against these false charges."

16:19 EDT Airspan Networks chosen by Mercury Broadband as lead RAN vendor - Mercury Broadband has "selected Airspan Networks as the lead RAN network supplier for CBRS Fixed Wireless Access solutions to provide broadband connectivity and enhanced services to its customers in several U.S. Midwestern states. As part of its rural broadband network expansion, Mercury Broadband has purchased and deployed hundreds of CBRS radios, equipment and software from Airspan, designed to significantly expand construction and operations of its rural broadband network. Mercury is a major winning bidder of federal funds from the Rural Digital Opportunity Fund, a US Federal Communications Commission initiative planned to close the digital divide in the US through the deployment of rural broadband networks."

16:17 EDT Disney drops 3% to $127.95 after Netflix reports Q1 subscriber loss

16:17 EDT IBM up 3% to $133.50 after Q1 results beat estimates

16:15 EDT Johnson & Johnson announces $77M opioid settlement with Alabama - Johnson & Johnson announced a settlement agreement with the State of Alabama and its participating subdivisions resolving current and future opioid-related claims against the company. With this agreement, the company is removed from filed cases in the state. The $77M settlement with Alabama is consistent with the framework of the recently finalized nationwide opioid settlement agreement, J&J said in a statement. "This settlement is not an admission of any liability or wrongdoing and the Company will continue to defend against any litigation that the final agreement does not resolve," it added. Reference Link

16:12 EDT IBM reports Q1 net cash from operating activities of $3.2B; free cash flow $1.2B

16:09 EDT TaskUs acquires heloo, terms undisclosed - TaskUs announced that it has acquired heloo, a European provider of outsourced specialized services. Founded in 2017, Croatia-based heloo provides digital customer experience solutions to European technology companies. Its employees support 20 languages across seven additional Eastern European countries, including Bosnia, Serbia, and Slovenia. With its omnichannel and remote workforce delivery model, heloo has a track record of delivering double-digit revenue growth.

16:08 EDT EuroDry to acquire M/V Santa Cruz for $15.75M - EuroDry announced that it has agreed to acquire M/V Santa Cruz, a 76,440 dwt drybulk vessel built in 2005, for $15.75M. The vessel was controlled by an un-affiliated third party and has been managed by Eurobulk, also the manager of the majority of the company's vessels. The vessel is expected to be delivered to the company around the end of April. The company will also assume the existing charter of the vessel at $14,800 per day until July. The acquisition will be financed with own funds.

16:07 EDT Netflix says goal to sustain double digit revenue growth - Netflix said: "Our goal is to sustain double digit revenue growth, increase operating income even faster (as we expand margins) and generate growing positive free cash flow. During this period of slower revenue growth, assuming no material swings in foreign exchange, we aim to protect our profitability and manage to a minimum operating margin roughly in line with current levels (i.e., this year's 19-20% guidance). Once we've re-accelerated revenue growth, we're committed to steadily growing our operating margin."

16:05 EDT Monolithic Power gets 3rd party ISO26262 functional safety product development - Monolithic Power Systems announced the achievement of independent third-party certification of its ISO26262 Functional Safety Product Development Process. The ISO26262 international standard has become a core requirement to address the risks of failure in electrical and electronic systems as the automotive industry pursues increasingly autonomous, connected, and electrified cars.The Functional Product Development Process ensures that applicable automotive products are able to help customers meet various Automotive Safety Integrity Level, or ASIL, requirements. The ISO26262 standard identifies four ASIL ratings, ranging from A to D. ASIL A represents the lowest degree of automotive hazard , while ASIL D represents the highest degree of automotive hazard (ex. for autonomous drive compute). As electronic systems in vehicles become more sophisticated and critically or solely relied on to provide oversight and control, it is necessary that they are developed with the highest degree of rigor. This third-party certification by the renowned experts at TUV-SUD ensures that MPS's new line of functional safety automotive-grade products has been developed using a process that follows the guidelines stipulated by the ISO26262 standard, and is suitable for up to ASIL D.

16:03 EDT Netflix sees Q2 global streaming paid net losses of 2.0M members - Netflix said in its quarterly letter to investors: "For Q2'22, we forecast paid net additions of -2.0m vs. +1.5m in the year ago quarter. Our forecast assumes our current trends persist (such as slow acquisition and the near term impact of price changes) plus typical seasonality (Q2 paid net adds are usually less than Q1 paid net adds). We project revenue to grow approximately 10% year over year in Q2, assuming roughly a mid-to-high single digit year over year increase in ARM on a F/X neutral basis. We still target a 19%-20% operating margin for the full year 2022, assuming no material swings in F/X rates from when we set this goal in January of 2022."

16:01 EDT Triumph Group adopts new company brand and modernized logo - Triumph Group announced that it is adopting a new company brand and modernized logo. The company's new identity, Triumph, reflects its one company, many solutions operating philosophy and recent streamlined organization and follows the company's transformation to focus on its core products and services. The new logo features a sleek version of the company's classic "T" symbol, with horizontal arms raised, indicating elevation and upward momentum. The mark also suggests a high-tech aircraft, a nod to forward velocity and progress. The company will continue to trade using the stock symbol "TGI."

15:24 EDT SSE to acquire wind farm portfolio from Siemens Gamesa for EUR580M in cash - Siemens Gamesa Renewable Energy (GCTAF), through Siemens Gamesa Renewable Energy Wind Farms, has signed a share purchase agreement with SSE Renewables International Holdings Limited (SSEZY) for the sale of a large portfolio of wind energy development projects in Spain, France, Italy and Greece. The portfolio comprises approximately 3.9GW of onshore wind capacity. A team of around 40 persons from Siemens Gamesa, with strong sector experience in the aforementioned countries, would be integrated in SSER as part of the agreement. The purchase price to be paid by SSER on completion will be EUR580M in cash, subject to customary post-closing adjustments. When completed, the purchase price would translate into an almost equivalent amount of revenues and a slightly lower contribution at EBIT pre-PPA and I&R costs given transactional costs, book value and other items of c. 5% of the purchase price. Further, in the context of the transaction, an agreement between Siemens Gamesa and SSER, which includes certain partnership rights for the supply of wind turbine generators and long-term maintenance services, has also been signed by the parties for a portion of wind farms installed and operated by SSER in the next few years coming from the portfolio to be sold. Completion of the transaction is conditional on foreign investment clearance in Spain, France and Greece and on the completion of a customary carve-out process of the assets being sold. It is expected that completion will take place during Siemens Gamesa's fiscal year 2022. As soon as completion takes place, Siemens Gamesa will inform.

14:12 EDT FDA says genetic non-invasive prenatal screening tests may have false results - The FDA issued a Safety Communication dated April 19 that states in part: "The U.S. Food and Drug Administration is warning patients and health care providers about the risks of false results with genetic non-invasive prenatal screening, or NIPS, tests, sometimes called noninvasive prenatal testing or tests, or NIPT. Results from NIPS tests can provide information about the possibility of a fetus having certain genetic abnormalities that could result in a child being born with a serious health condition. While health care providers widely use NIPS tests, none have yet been authorized, cleared, or approved by the FDA. The accuracy and performance of NIPS tests have not been evaluated by the FDA and these tests can give false results, such as reporting a genetic abnormality when the fetus does not actually have one. NIPS tests are screening tests, which means the NIPS test may only tell you the risk of the fetus having certain genetic abnormalities. They are not diagnostic tests, which are generally used to more definitively confirm or rule out a suspected genetic abnormality... The FDA is aware of cases where a screening test reported a genetic abnormality and a confirmatory diagnostic test later found that the fetus was healthy. Given the increased use of these tests and concerns raised in recent media reports, the FDA is providing this information to educate patients and health care providers and to help reduce the inappropriate use of NIPS tests. The FDA recommends that patients discuss the benefits and risks of NIPS tests with a genetic counselor or other health care provider before deciding to get these tests." Reference Link

13:31 EDT Motorola Solutions acquires Calipsa, terms not disclosed - Motorola Solutions announced it has acquired Calipsa, Inc., a technology firm in cloud-native advanced video analytics based in London, U.K. The company said, "Calipsa's scalable platform enables businesses to optimize security with AI-powered analytics that verify alarms, enable content-based searches, detect tampering and assess the health of cameras in real time. The solution is relied upon by enterprise and security monitoring customers around the world. Calipsa's unique cloud-based technology allows customers to add AI to existing IP-based cameras without additional hardware, enabling new analytics capabilities on the millions of IP-based cameras already deployed." Terms of the transaction were not disclosed.

12:32 EDT Southern Company raises annual dividend by 8c per share to $2.72 per share - Southern Company announced it is increasing its dividend by 8c per share on an annualized basis to a rate of $2.72 per share. Southern Company also announced a regular quarterly dividend - including the increase of 2c per share over the prior quarter - of 68c per share, payable June 6, 2022, to shareholders of record as of May 16, 2022. "The excellent customer service, performance and resilience of Southern Company's superior energy businesses serves as the foundation for our overall shareholder value proposition that for decades has included dividends and dividend growth," said Southern Company chairman, president and CEO Thomas A. Fanning. "Today's action by the board reinforces our objective to provide regular, predictable, sustainable earnings-per-share and dividend growth supported by premier state-regulated utilities and energy infrastructure under long-term contracts."

12:30 EDT Lucasfilm Games, Amy Hennig's Skydance working on new 'Star Wars' game - Skydance New Media announced a collaboration with Lucasfilm Games, a subsidiary of Disney, to develop and produce a narrative-driven, action-adventure game featuring an original story in the "Star Wars" galaxy. Helming Skydance New Media is award-winning writer and director Amy Henning, whose credits include the blockbuster series "Legacy of Kain," "Jak and Daxter," and "Uncharted." "I've often described how seeing Star Wars in 1977 essentially rewired my 12-year-old brain, shaping my creative life and future indelibly," said Hennig, president, Skydance New Media. "I'm elated to be working with Lucasfilm Games again to tell interactive stories in this galaxy that I love." Reference Link

12:06 EDT Southwest Gas: Objective of strategic alternatives process is to maximize value - Southwest Gas Holdings issued the following statement commenting on an open letter to Southwest Gas stockholders published by Carl Icahn on April 19, 2022. "Our one and only objective is to maximize value for stockholders by expeditiously conducting a review of strategic alternatives. As we stated in our press release, Mr. Icahn is welcome to be part of the sale process and we are confident that he will realize that this is a competitive process, overseen by a committee of independent directors, in which the only "preferred buyer" cited by Mr. Icahn will be the party that provides the best value for stockholders." On April 18, 2022, Southwest Gas announced that, as a result of the receipt of an indication of interest well in excess of Carl Icahn's $82.50 per share offer, the Southwest Gas Board has authorized the review of a full range of strategic alternatives to maximize stockholder value.

12:03 EDT IMAX appoints Natasha Fernandes as CFO - IMAX Corporation announced it is promoting Natasha Fernandes to the role of CFO, effective May 1. A 15-year veteran of the Company's Finance team, Fernandes most recently served as Deputy CFO for IMAX. She succeeds Joseph Sparacio, who served as the Company's CFO from 2007 to 2016, and rejoined IMAX last year as the Company's interim CFO. Fernandes will report directly to Rich Gelfond, CEO of IMAX Corporation.

12:00 EDT BRC Inc. falls -13.8% - BRC Inc. is down -13.8%, or -$3.17 to $19.83.

12:00 EDT Silvergate Capital rises 14.3% - Silvergate Capital is up 14.3%, or $16.61 to $132.92.

12:00 EDT Ultrapetrol rises 96146.8% - Ultrapetrol is up 96146.8%, or $48.07 to $48.12.

11:33 EDT Hasbro appoints Shane Azzi as CSCO, Matt Austin as COO - Hasbro (HAS) announced that Shane Azzi will join the company as chief global supply chain officer, and that Matt Austin, previously President of Hasbro Europe and Asia, has been named chief commercial officer. Both Shane and Matt will report to Eric Nyman, Hasbro's President and COO. Shane will work to position Hasbro's supply chain as a competitive advantage, creating value and building flexibility and resilience to exceed customer expectations. He will oversee global supply planning, global sourcing and procurement, logistics and fulfillment, quality assurance and security. Shane most recently serving as Chief Supply Chain Officer for Kimberly-Clark (KMB). In addition, Hasbro has promoted Matt Austin to CCI where he will leverage Hasbro's commercial opportunities with powerful, data-driven consumer insights and strategic partnerships across different channels, including e-commerce and direct fan experiences, to continue to drive profitability and growth. He assumes this position following the retirement of CCO Michael Hogg at the end of March. Shane will join Hasbro on May 4th following the retirement of Tom Courtney, Executive Vice President & Chief Global Operations Officer, who moved into an advisory role on April 1, 2022 after 30 years with the company and will retire at the end of 2022. A successor to Matt as President for Europe and Asia will be named in the coming months.

11:32 EDT Nintendo's 'Xenoblade Chronicles 3' out July 29 - Nintendo said that its upcoming Switch exclusive role-playing game "Xenoblade Chronicles 3" will be releasing sooner than expected, now set to come out July 29. The title was originally set for release in September 2022. Reference Link

11:09 EDT Lockheed Martin sees international wins adding 235 F-35s to backlog

11:04 EDT Lockheed Martin 'well on our way' to $4B in share repurchases this year - Comments taken from Q1 earnings conference call.

11:02 EDT Lyft makes masks optional while riding or driving - Lyft (LYFT) announced in a blog post: Soon after the pandemic began, Lyft established new in-ride policies based closely on public health guidance from the Centers for Disease Control and Prevention (CDC). Now that the CDC order mandating masks on transportation is no longer in effect, starting today, we're updating our policies for riding and driving with Lyft. Here's what that means for riders and drivers: Wearing a mask is now optional for everyone in the car. Riders and drivers are no longer required to keep the front seat empty or the windows open. While riders and drivers can always cancel any ride they don't wish to take, health safety reasons - like not wearing a mask - will no longer appear as cancellation options in the app; Riders and drivers should continue to not use Lyft if they have COVID-19 or any related symptoms. Wearing masks on transportation may still be required by law in some areas, and we encourage riders and drivers to check their local public health requirements before using Lyft. We know that everyone has different comfort levels, and anyone who wants to continue wearing a mask is encouraged to do so." Uber (UBER) announced earlier on Tuesday that it will no longer require riders or drivers to wear masks in the U.S. Reference Link

10:31 EDT Fifth Third expects FY22 revenue to be $275M more than January guidance - Consensus is $8.38B.

10:11 EDT Fifth Third sees 'resilient' share repurchases in Q4

10:07 EDT Wellbeing Digital says KGK finalizes two clinical study reports in Q1 - Wellbeing Digital Sciences is pleased to provide a commercial and corporate update regarding the recent achievements of its wholly-owned subsidiary, KGK Science. The company said, "The first quarter of 2022 has delivered significant opportunities for KGK as new contracts have been signed, clinical research reports have been completed, regulatory approvals have been obtained and other honours have been bestowed upon the CRO." During the first quarter of 2022, KGK's research team finalized two clinical study reports - a COVID-19 virtual study and an immune function study. Its regulatory team was able to complete gap analysis for a propriety delivery system in March and obtained regulatory approvals for two clinical trials that include a mood and an immune health clinical trial. The CRO's regulatory team also conducted claims reviews for two dietary supplement companies and one food company, as well as a label review for a dietary supplement. Regarding new business, KGK signed six contracts over the last month including an Ames study, three claims reviews, two path-to-market and gap analysis engagements, two product licence applications, a consulting project for claims regarding a supplement and a manuscript. Mal Evans, Chief Scientific Officer of KGK, will be serving as a judge for the 2022 Nutraingredients Awards, which will be her second year as a judge for these prestigious awards. Andrew Charrette, Director of Regulatory Affairs and Psychedelic Advisor at KGK, has been invited to be a panellist at Lift&Co. Expo in Toronto, Canada. KGK has also been invited to present virtually at Nutrition 2022 Live Online, the American Society for Nutrition's annual flagship meeting, on June 14 - 16, 2022.

10:03 EDT Toyota invests $383M in four U.S. manufacturing plants - Toyota will invest $383M in four of its U.S. manufacturing plants that build the heart of new Toyota and Lexus vehicles. The new investment supports the production of four-cylinder engines, including options for hybrid electric vehicles, at its Alabama, Kentucky, Missouri and Tennessee plants. Toyota Alabama: Huntsville, Ala., $222M: Toyota Alabama will create a new four-cylinder production line with the capacity to produce engines for both combustion and hybrid electric powertrains. Additionally, the facility will expand its footprint by 114,000 square feet, which marks the plant's sixth building expansion since 2003. Toyota Alabama has the capacity to build 900,000 engines annually and represents a nearly $1.5B investment. Toyota Kentucky: Georgetown, Ky., $16M: Toyota Kentucky is expanding flexibility of the four-cylinder engine line announced last fall, which will better position the plant to meet customer demand. The plant's powertrain facility can produce up to 600,000 units annually. Toyota Kentucky is the company's largest plant globally, producing seven Toyota and Lexus models, as well as four-cylinder and six-cylinder powertrains. Overall, the plant represents an $8.5B investment. Toyota Missouri: Troy, Mo., $109M: Toyota Missouri's investment provides new equipment to build four-cylinder engine heads on three production lines. The plant has the capacity to build more than 3 million cylinder heads annually and represents a $564M investment. Toyota Tennessee: Jackson, Tenn., $36M: Toyota Tennessee will update equipment to build new four-cylinder engine blocks. The plant has the capacity to produce more than 2 million engine blocks annually and represents a $425M investment.

10:00 EDT Telephone and Data falls -7.7% - Telephone and Data is down -7.7%, or -$1.56 to $18.78.

10:00 EDT System1 falls -28.6% - System1 is down -28.6%, or -$5.86 to $14.60.

10:00 EDT American Campus rises 12.7% - American Campus is up 12.7%, or $7.33 to $64.91.

09:58 EDT Gol Linhas signs cargo, logistics services agreement with Mercado Livre - GOL Linhas (GOL) announced the signing of a landmark agreement between its logistics business, GOLLOG, which operates cargo services to 52 airports and over 3,900 destinations in Brazil, and Mercado Livre, which operates marketplaces for e-commerce and online auctions. The agreement, with a term of ten years, includes a dedicated freighter fleet of six Boeing (BA) 737-800 BCF and is expected to begin operations during 2H22. There is also the option of adding other six cargo aircraft by 2025. GOL plans to end this year with 136 aircraft in its fleet, comprised of 44 Boeing 737-MAXs and 92 Boeing 737-NGs. The introduction of the six-cargo aircraft is expected to generate fleet optimization savings of approximately R$25M in 2022 and another R$75M in 2023. The company's ongoing transformation to the 737 MAX will also enable greater dilution of fixed costs and generate new opportunities for ancillary revenues. GOL's agreement with Mercado Livre is part of the company's investment to serve the needs of the growing Brazilian e-commerce market, which generates over R$180B in annual revenues and a yearly spend of over R$12B on logistics services. As such, GOLLOG plans to increase its range of services and tonnage capacity by 80% during 2023 to generate additional incremental revenue of approximately R$100M in 2022, and more than R$1B over the next five years.

09:47 EDT United States Natural Gas Fund falls -8.3% - United States Natural Gas Fund is down -8.3%, or -$2.25 to $24.89.

09:47 EDT System1 falls -25.8% - System1 is down -25.8%, or -$5.27 to $15.18.

09:47 EDT UserTesting rises 13.2% - UserTesting is up 13.2%, or $1.16 to $9.96.

09:41 EDT Diffusion Pharmaceuticals trading resumes

09:34 EDT Johnson & Johnson says continues to invest in R&D at 'competitive levels' - Expects approximately 20 new product launches in 2022. Says inflation mitigation strategies are underway. Says separation timelines for two companies remain unchanged and expected in 2023. Will provide more details on split in 2H22. Says capital allocation strategies remain unchanged. Will continue to do "tuck-in" M&A. Says "we remain confident in our business." Comments taken from Q1 earnings conference call.

09:30 EDT Robinhood acquires cryptoasset company Ziglu, terms not disclosed - Robinhood said it signed a deal to acquire Ziglu Limited, a U.K.-based electronic money institution and cryptoasset firm. "With Ziglu, UK-based customers can buy and sell eleven cryptocurrencies, earn yield via its 'Boost' products, pay using a debit card, and move and spend money, even abroad, without fees," the company said in a blog post. "In the near term, nothing will change for current Ziglu customers. Longer term, we'll integrate Ziglu more fully into Robinhood, bring the Robinhood brand overseas, and work to expand operations beyond the UK into Europe," it added. Ziglu was valued at GBP 85M last November when it raised GBP 7M, according to the Financial Times. Reference Link

09:25 EDT Tenable Holdings announces enhancements to partnership with ServiceNow - Tenable (TENB) announced enhancements to its partnership with ServiceNow (NOW) that bolster The Now Platform with asset inventory and vulnerability data from Tenable.ot. Utilizing Tenable's unified assessment and remediation guidance, this new integration streamlines asset inventory and centralizes IT and operational technology, OT, remediation workflows across converged industrial environments. Tenable's latest integration with ServiceNow provides visibility and control over OT assets with the same tools and processes that were traditionally reserved for IT assets. "As industrial networks become increasingly more complex with a mixture of IT and OT, it is more critical than ever to know what assets and vulnerabilities are in your environment," said Ray Komar, vice president of technical alliances, Tenable. "The days of managing multiple spreadsheets across disparate teams are over. We're excited to partner with ServiceNow providing our joint customers a unified view of the attack surface, and empowering security teams to remediate threats."

09:21 EDT EzFill signs fleet fueling agreement with Buggy in Miami - EzFill (EZFL) announced a new fleet agreement with Buggy, effective immediately. EzFill will provide regular mobile fuel service for Buggy, a car rental company for drivers on-demand ridesharing services in the Miami area. Buggy has more than 6,000 cars on the street in the U.S. and Mexico. Through its partnership with Uber (UBER), drivers receive free maintenance and 24/7 support. "Thanks to our reliable mobile fuel delivery service, Buggy's customers will have peace of mind knowing they are renting fully fueled vehicles, which allows them to spend more time focusing on serving their passengers instead of having to look for local stations to fill up their tanks," said Mike McConnell, CEO of EzFill.

09:18 EDT Cyclacel doses first patient in Phase 1/2 study of oral CYC140 - Cyclacel Pharmaceuticals announced dosing of the first patient in the Company's streamlined, multi-cohort Phase 1/2 study of oral CYC140 in patients with advanced solid tumors and lymphomas. "With the start of this trial, Cyclacel is now enrolling patients across three registration-directed studies to evaluate safety and efficacy of our two lead drug candidates, fadraciclib and CYC140, for the treatment of various solid tumors, lymphomas and leukemias," said Spiro Rombotis, Cyclacel's President and Chief Executive Officer. "As with the fadraciclib studies, the Phase 1 stage of this trial will determine an optimal dosing regimen of oral CYC140 and provide insights with respect to safety, tolerability and clinical activity. The Phase 2 stage will enroll up to seven cohorts by histology and also a basket cohort. We expect initial data from this trial during the first half of 2023. We also look forward to reporting initial data from the fadraciclib clinical study in advanced solid tumors during the first half of 2022." The Phase 1/2 registration-directed trial, designated CYC140-101, uses a streamlined design and will first determine in a dose escalation stage the recommended Phase 2 dose for single-agent CYC140.

09:17 EDT Terreno Realty acquires $17.3M industrial property in Newark - Terreno Realty acquired an industrial property in Newark, New Jersey on April 18 for a purchase price of approximately $17.3M. The 9.7-acre improved land parcel at 87 Doremus Avenue is adjacent to Exit 15E of the New Jersey Turnpike and Terreno Realty Corporation's 85 Doremus Avenue property. The property is 100% leased to two tenants, one of which is on a short-term basis, and the estimated stabilized cap rate is 5.3%.

09:17 EDT Petros Pharmaceuticals announces results of OTC label comprehension study - Petros Pharmaceuticals provides positive results from its over-the-counter, OTC, draft label comprehension study for its erectile dysfunction, ED, drug STENDRA, which demonstrate understanding of the messages therein. These results suggest that the draft drug facts labeling language as written may be appropriate for submission to the FDA for review for over-the-counter labeling. The Pivotal Label Comprehension Study compiled 453 label comprehension interviews - including a significant cohort of low health literacy individuals - to determine comprehension of draft drug facts labeling for STENDRA. In summary, the proposed over-the-counter labeling was well understood, according to the study parameters, by those consumers who participated. "The results of this label comprehension study help us to continue to solidify our plans to apply to the FDA to help expand access for STENDRA beyond the prescription model, and, if approved by the FDA, to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States," commented Fady Boctor, Petros's President and Chief Commercial Officer. "The switch to OTC is one of many approaches we are currently exploring to expand access to STENDRA. We remain steadfast in our dedication to men with ED by providing new and innovative options to help them safely, securely, and discreetly obtain this medication."

09:16 EDT Lexaria Bioscience commences human clinical hypertension study - Lexaria Bioscience is pleased to announce that it has begun its multi-week human clinical hypertension study. The study, HYPER-H21-4, is a randomized, double blinded, placebo-controlled, cross-over study in 60 people and the most comprehensive study ever undertaken by Lexaria. Dosing in more than half the volunteers has already commenced ahead of schedule, with all treatment visits expected to conclude in early July, 2022. Baseline brain magnetic resonance imaging scanning has also already begun. Of significant note, there have been no serious adverse events reported by these volunteers, demonstrating that DehydraTECH-CBD has been well tolerated in those that have received it thus far. HYPER-H21-4 is designed to enhance Lexaria's probability of success with its expected subsequent Investigational New Drug application filing to seek Food and Drug Administration approval to commence registered clinical testing at the Phase I level or higher, to be determined in consultation with the FDA. This human study is also expected to enhance Lexaria's understanding of DehydraTECH-CBD for the treatment of cardiovascular and other disease states beyond hypertension related to increased arterial stiffness, pursuant to earlier promising findings in this area. HYPER-H21-4 follows Lexaria's previously announced successes in significantly reducing blood pressure in similarly hypertensive human volunteers in its 2021 studies HYPER-H21-1 and HYPER-H21-2. This study is entirely funded through the Company's existing cash resources and is not subject to any financing requirement. Independent Review Board approval was received in December 2021. The clinical test articles for this study have been manufactured, quality control tested and shipped to the European research hospital conducting the study. HYPER-H21-4 consists of a minimum of 60 volunteers between the ages of 40-70 with documented or measured elevated blood pressure, mild hypertension or moderate hypertension who will use DehydraTECH-CBD every day for a 5-week duration. DehydraTECH-CBD doses will escalate between a range of 225 mg/day to 450 mg/day over the study duration. Some volunteers will already be using leading standard of care hypertension drugs such as angiotensin-converting enzyme inhibitors with or without diuretics and/or calcium channel blockers, which will help evaluate the efficacy of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study will allow Lexaria to gather critical data monitoring the safety and efficacy of DehydraTECH-CBD over time and will evaluate the potential for longer term health benefits. HYPER-H21-4 is more comprehensive than any work previously undertaken by Lexaria and many types of analysis will be performed including 24-hour ambulatory blood pressure, which is the primary study outcome. Secondary study outcomes include: vascular health including arterial stiffness and autonomic balance; electrocardiogram analysis; brain structure and function through MRI testing; blood biomarkers; renal and hepatic analysis, sleep quality / daytime sleepiness / sleep disorders; actigraphy, geriatric depression scale, perceived stress, and Beck anxiety inventory. Each of these sets of data may lead to additional applications for DehydraTECH-CBD. For example, the MRI data may assist one of the secondary outcome measurements in the study to evaluate possible positive effects upon brain structure and function; and the detailed psychometric testing may reveal new insights into the potential benefits for mental health. The wide range of data collection could provide additional insights into the long-term health benefits of DehydraTECH-CBD that might otherwise remain undetected. Lexaria will provide further updates on the progress of study HYPER-H21-4 and its IND application enabling program as they become available. Details on the outcomes after the expected July conclusion of all treatment visits in study HYPER-H21-4 will follow in due course after performing the necessary data analyses.

09:13 EDT Progyny, RESOLVE to launch national infertility awareness week - Progyny and RESOLVE: The National Infertility Association announced both organizations will ring the Nasdaq Stock Market Opening Bell on Tuesday, April 26, 2022. The next day, on Wednesday, April 27, 2022, the partners will light the top of the Empire State Building, in orange, the official color for infertility awareness. The following evening, April 27, Progyny and RESOLVE will flip the ceremonial switch to light the top of the Empire State Building to recognize and give voice to the millions of people who struggle to build their families. "Progyny's mission is to make dreams of parenthood come true. As the fertility benefits provider of choice for hundreds of the world's leading brands and Fortune 500 companies, we have already helped more than 100,000 people on their family building journeys," said Pete Anevski, CEO of Progyny. "While National Infertility Awareness Week is only a seven-day period dedicated to the cause, we believe that the impact of our New York City takeover will echo across the country. We are honored to play a role in celebrating the strength of everyone who has struggled to build their families, during this week and always."

09:11 EDT ModivCare announces Brett Hickman as company's Chief Commercial Officer - Modivcare announced the appointment of Brett Hickman as the Company's Chief Commercial Officer. In this role, Mr. Hickman will be integral to Modivcare's commercial strategy to cross-sell its integrated platform of supportive care solutions that address the social determinants of health, as well as drive organic revenue growth and maintain the Company's existing customer base.

09:11 EDT Phunware partners with Accion Labs for mobile solutions - Phunware announced that it has entered into a strategic partnership with Accion Labs. Accion will be designated as a preferred partner in the implementation and customization of Phunware's Multiscreen-as-a-Service platform to all current and future clients interested in deploying mobile solutions to drive digital transformation. To support this role, Accion will have direct access to developer resources and support from Phunware in bringing implementations to market for its customers. Phunware will also be able to leverage Accion's infrastructure to support its clients that require additional services beyond what MaaS offers. The resulting center of excellence will make Phunware's MaaS platform the mobile solution of choice for Accion's international digital transformation services spanning 22 countries and supported by more than 5,000 employees.

09:09 EDT Codorus Valley announces board, committee appointments - Codorus Valley Bancorp (CVLY), parent company of PeoplesBank, A Codorus Valley Company, has appointed John Kiernan, Esq. to the Board of Directors effective April 12, 2022. Kiernan will serve the remainder of the term as a Class C Director of the Company until the annual meeting of shareholders in 2022. In addition, Kiernan has been appointed to the Corporate Governance and Nominating Committee, the Audit Committee, and the Compensation Committee of the Board. Kiernan serves as President and Chief Executive Officer of Alico (ALCO).

09:09 EDT Zoom Video announces availability of Zoom Whiteboard - Zoom Video Communications announced the general availability of Zoom Whiteboard, a modern digital canvas that provides a unified solution for collaboration and creation within the Zoom platform. Users can interact with the Zoom Whiteboard similar to an in-person experience, creating more visually engaging and efficient collaboration. With the global workforce embracing hybrid work environments across industries, there is an increased need for solutions that seamlessly foster ideation and teamwork among co-located and distributed colleagues. Zoom Whiteboard further broadens the capabilities of the Zoom platform for today's hybrid workforce, including unified communications, Zoom Developer Platform, Zoom Events, Zoom Contact Center, and Zoom IQ for Sales.

09:07 EDT Fluent partners with Cadent to launch audience segments for TV marketing - Fluent announced its partnership with Cadent. Through this partnership, marketers can activate Fluent audience segments across key categories such as health, finance, and political via Cadent Aperture Audience Data Marketplace. "Given the exponential rise in connected TV viewership and an estimated 1.9 billion subscription OTT service users worldwide, we're proud to partner with Cadent to make our declared and permissioned data easily accessible to advertisers for their advanced TV marketing initiatives," said Brian Hogan, Fluent's EVP and GM, Data Solutions. "Most notably, our health and wellness audience segments will help to drive innovation among pharmaceutical advertisers as they begin to leverage this emerging channel."

09:07 EDT PharmaCyte Biotech announces results from pancreatic cancer clinical trial - PharmaCyte Biotech announced that the empty capsule material that comprises its pancreatic cancer clinical trial product candidate does not cause systemic toxicity. The study, which was performed by a third-party contract research organization, involved the ISO compliant testing of an extract of empty cellulose sulphate capsules provided by Austrianova for potential acute systemic toxicity in mice, according to ISO 10993-11: 2017, an FDA recognized consensus standard. Upon intraperitoneal injection of capsule extract, the mice were observed for clinical signs of toxicity at 30 to 40 min, 1 hour, 2 hours and 4 hours post dosing on day 1. On days 2, 3, 7 and 14, all of the animals were observed once daily for clinical signs and twice daily for mortality. The body weight of the mice was recorded prior to administration of the capsule extract on day 1 and on days 2, 3, 4, 7 and 14 during the observation period. At the end of observation period, all the animals were examined for signs of toxicity. The analyses revealed that none of the mice died or showed any clinical signs of toxicity or gross pathological changes as compared to control mice. Moreover, no treatment related changes were noted in body weight and percent change in body weight with respect to day 1 values and all animals revealed a normal increase in body weight during the observation period.

09:06 EDT Senmiao Technology launches its ride-hailing platform in four new cities - Senmiao Technology announced the launch of its proprietary online ride-hailing platform for drivers in four cities in China: Qingdao, Nanchang, Jinhua, and Yancheng. A total of over 3,600 rides have been completed in these four cities on Senmiao's online ride-hailing platform since it was launched in March 2022. With the addition of Qingdao, Nanchang, Jinhua, and Yancheng, Senmiao's platform is now available in 19 cities across China, including six cities in Sichuan Province and 13 major cities in other provinces in China.

09:05 EDT Phunware announces strategic partnership with Accion Labs - Phunware announced that it has entered into a strategic partnership with Accion Labs, an innovation engineering company specializing in emerging technologies and digital transformation. Accion will be designated as a preferred partner in the implementation and customization of Phunware's Multiscreen-as-a-Service, or MaaS, platform to all current and future clients interested in deploying mobile solutions to drive digital transformation. To support this role, Accion will have direct access to developer resources and support from Phunware in bringing implementations to market for its customers. Phunware will also be able to leverage Accion's infrastructure to support its clients that require additional services beyond what MaaS offers.

09:04 EDT GitLab granted software licensing program contract with California - GitLab announced that it has become an approved vendor under the Software Licensing Program with the State of California. This contract allows state and local agencies, including educational institutions in California, to purchase GitLab software licenses at an agreed-upon discount, reducing costs and streamlining the procurement process. Under the contract, agencies will have greater access to GitLab's complete DevOps solution, which empowers organizations to deliver software faster and more efficiently.

09:04 EDT Arthur J. Gallagher acquires Hinsdale and its subsidiary Mavco Insurance - Arthur J. Gallagher & Co. announced the acquisition of Hinsdale, IL-based G.A. Mavon & Co. and its Mavco Insurance Agency, subsidiary. Terms of the transaction were not disclosed. Founded in 1916, G.A. Mavon & Co. is a fourth-generation, family-run, standard and specialty lines wholesale broker. Mavco Insurance Agency, founded in 1972, is its retail insurance agency subsidiary. Both firms serve the insurance needs of high-net-worth personal lines clients, as well as commercial business owners, with a focus on professional lines.

09:03 EDT LPL Financial launches Paraplanning Services - LPL Financial announced that the firm's advisors, RIAs and institutions can now access Paraplanning Services. LPL's newest offering provides advisors with experienced support through the use of paraplanners to deliver financial planning services to clients to help them grow their capacity to deliver personalized advice. The Paraplanning Services team operates as an extension of the advisor's practice, working together with advisors to learn about their clients' needs. Paraplanners gather and input data into financial planning software, such as eMoney, WealthVision, MoneyGuidePro and Right Capital, to generate insights and provide advisors with a complete financial plan for their clients. This plan becomes the guide for advisors and their clients, with plan maintenance available on an annual basis.

09:02 EDT PHX Minerals announces acquisition in the Haynesville play for $5.10M - PHX Minerals announced a mineral and royalty acquisition targeting the Haynesville play in East Texas and Louisiana. PHX has agreed to acquire approximately 506 net royalty acres for aggregate consideration of $5.10M in cash from a private seller subject to customary closing adjustments. The transaction will be funded with a combination of cash on hand and borrowings under our existing credit facility. The Board of Directors of PHX unanimously approved the Acquisition, which is subject to certain closing conditions and is expected to close by May 27.

09:02 EDT Chipotle announces $50M new venture fund - Chipotle Mexican Grill announced the formation of Cultivate Next, a new venture which intends to make early-stage investments into strategically aligned companies that further the Company's mission to Cultivate a Better World. Cultivate Next's aim is to support seed to Series B stage companies that can accelerate the company's strategic priorities such as running great restaurants, amplifying technology and innovation, further advancing its Food With Integrity mission, and expanding access and convenience for consumers. The new venture fund will have an initial size of $50M and will be financed solely by Chipotle.

09:00 EDT Esports Technologies announces agreement with Incentive Games - Esports Technologies announced a software license and service agreement between subsidiary Esports Marketing Technologies and Incentive Games. Incentive has established itself as a top developer of premium free-to-play games for casino, sports betting, and fantasy sports operators. Through this agreement, Incentive will build customized free-to-play games for Esports Technologies brands. The first free-to-play game will be created using Counter Strike: Global Offensive wagering markets, with plans to expand to Dota 2, League of Legends, and Valorant. These games will be designed with engaging game mechanics to acquire and retain customers, while increasing their lifetime value.

08:49 EDT Sparta Commercial Services signs ZAGMotoX for iMobileApp - Sparta Commercial Services announces that ZAGMotoX chose Sparta's iMobileApp to enable their customers to easily find and purchase a broad selection of aftermarket parts and accessories.

08:48 EDT Omniq announces purchase order to deploy its AI-based VRS in South America - OMNIQ announced it was awarded a follow on contract to from a global leading high-end defense solutions, enterprise to deploy OMNIQ's AI based Machine Vision solution in a district of Uruguay, to provide a Safe District project. The project started approximately four years ago and now local authorities decided to extend the project and order additional systems from omniQ and upgrade with additional new features offered by omniQ. The Safe District project includes OMNIQ's sensors with AI based Vehicle Recognition System, VRS, that will allow the operators of the control room to obtain real-time data from the field and alert law enforcement officials, including logistics and emergency personnel, in conjunction with the nature of the event. "We are proud to have won this Safe District contract, demonstrating once again the value of our AI based solution for a variety of verticals with multibillion dollars potential. I am sure that many more customers have similar needs and hope will follow the Uruguay authorities, the Israeli Government and the Cities in the US that already contracted us and will choose our sophisticated "battle proven" solution as the means to improve public safety." Commented Shai Lustgarten, CEO of OmniQ Corp.

08:47 EDT Williams to collaborate with Cheniere Energy on QMRV of GHG emissions - Williams (WMB) announced that it will collaborate with Cheniere Energy (LNG), as well as other natural gas midstream companies, methane detection technology providers, and academic institutions to implement quantification, monitoring, reporting and verification, or QMRV, of greenhouse gas, or GHG, emissions at natural gas gathering, processing, transmission, and storage systems. This collaboration with Cheniere will improve the overall understanding of GHG emissions and further the deployment of the most advanced monitoring technologies and protocols to enhance clean energy supply and delivery for Williams and its customers.

08:46 EDT Bebuzee opens new offices in Miami in anticipation of launch of its 'Super App' - The executive management of Bebuzee announced that it has now opened an office in Brickell, Miami and will be moving about 25 employees to the Miami office in anticipation of the release of its "Super App"... Bebuzee, which will be launched in the coming months. The Company is also setting up servers in Frankfurt, Amsterdam, Milan and Miami to handle over 150M users when the app is launched. Joseph Onyero, Chief Executive Officer of Bebuzee, said: "Bebuzee is the only social media platform to localize its contents for specific countries... It was obvious that most social media platforms were generic and only local postings in each community made those platforms somewhat relevant to the local communities. Bebuzee has localized its platform for most countries by providing Local content such as news and information and also movies, documentaries, series, talk shows not posted anywhere else, all from over fifty movie studios granting exclusive rights for a limited period of new release before it is launched to the public. Add new releases weekly from these producers, and Bebuzee becomes the premiere supplier of entertainment and information globally, serving all of this at no cost to the viewer."

08:43 EDT Bridgeline Digital announces site search product chosen by large distributor - Bridgeline Digital announced that their site search product has been chosen by a large industrial distributor to power their online store. Ari Kahn, CEO of Bridgeline says, "Bridgeline has continued to grow within the B2B distribution industry, especially in electrical, automotive, and industrial. Our site search product has unique features designed for the complexity of B2B catalogs that are appealing to manufacturers and distributors."

08:42 EDT Dentsply Sirona CEO Don Casey terminated, John Groetelaars named interim CEO - DENTSPLY SIRONA announced the appointment of John Groetelaars, who serves on Dentsply Sirona's Board of Directors, as Interim CEO. He succeeds Don Casey, who has been terminated as CEO and will cease to serve as a member of the Company's Board, effective immediately. The Board has initiated a search to identify the Company's next CEO and has retained a leading executive search firm to support the process.

08:40 EDT New York Times announces Joseph Kahn as executive editor - The New York Times announced that Joseph Kahn has been named executive editor, effective June 14. In this role, Kahn will oversee all aspects of The Times's global newsroom. Kahn, a two-time Pulitzer Prize-winning journalist who has been managing editor at The Times since September 2016, will succeed Dean Baquet.

08:38 EDT Staffing 360 Solutions to acquire Headway Workforce Solutions for up to $14M - Staffing 360 Solutions announced that it has signed an agreement to acquire Headway Workforce Solutions for up to approximately $14 million in a combination of stock and cash. The acquisition is subject to the satisfaction of certain closing conditions. Upon closing, $9 million will be paid through issuance of shares of preferred stock that are convertible into approximately 3.5 million common shares, and up to $5 million cash through an earn-out. With a 35-year history and a national reach of human capital workforce solutions, Headway reported unaudited revenues of $85 million in 2021. Headway offers customized contract-based workforce solutions in all 50 states, providing full scope staffing. Headway's leading blended business service model of high-touch technology-driven-processes encompasses two integral components: Recruitment & Staffing; Superior Recruitment Results. CORE is based on a foundation of proprietary and integrated processes and technologies to source the best candidates via its flexible and customizable strategy and execution. A proprietary database of three million candidates supports job search campaign management and is augmented with advanced e-recruiting technologies and integrated with a sophisticated applicant tracking system. Headway is one of the largest US providers of survey research personnel with projects in the social sciences, healthcare and marketing sectors. Its unique survey research niche is a valuable tool and differentiator in the staffing industry, providing these services in every zip code of the US.

08:38 EDT Badger Meter expects near term unevenness - Bockhorst continued, "We delivered strong revenue growth in the quarter which was enabled by a number of actions we have taken, and continue to execute, to improve operating resiliency. It was also the result of our longstanding 'choice matters' portfolio of solutions designed to fulfill varied customer needs. While recent geopolitical events have increased the level of supply chain uncertainty and accelerated inflationary pressures in an already difficult environment, we continue to act quickly to secure supply and to strategically price our solutions aligned with the value we deliver. While near term unevenness appears to be the norm, we remain confident in our ability to execute in the face of these challenges. Our optimistic long-term outlook is built on strong industry demand fundamentals, strategic customer successes and our comprehensive offering of innovative and tailorable smart water solutions that we believe will extend our market leadership. We are actively addressing customer requirements to enhance operational efficiency and resiliency by leveraging our industry-leading ORION Cellular endpoints and our BEACON digital platform to solve their water-related needs and challenges. We continue to execute our strategic growth plans to further expand these customer-centric solutions both organically, and through tuck-in technology acquisitions, utilizing our strong balance sheet."

08:35 EDT Allison Transmission earns certification from CARB for 2022 eGen Flex - Allison Transmission announced it has received certification from the California Air Resources Board CARB for the model year 2022 eGen Flex electric hybrid propulsion system paired with Cummins B6.7 and L9 engines. Since 2014, Allison has received annual certification from CARB for the Allison H 40/50 EP propulsion system. For the first time this year, the certification was awarded for the eGen Flex, the company's newest electric hybrid solution for transit buses and coaches. Introduced in 2020, the eGen Flex electric hybrid system is capable of traveling in electric-only mode for up to 10 consecutive miles or 50 minutes. This electric-only mode can be utilized multiple times per route and per day. In real world revenue service, Allison's eGen Flex has demonstrated the ability to operate in full engine off mode for more than 50% of its time in operation across multiple routes within one of North America's largest transit fleets. The eGen Flex is further capable of eliminating engine emissions and noise while loading and unloading passengers, in dense pedestrian areas, and in zero emission zones and bus depots. In addition, the eGen Flex improves fuel consumption by up to 25% versus a conventional diesel bus. "We are thrilled to receive CARB's certification for the eGen Flex, Allison's latest innovation in electric hybrid propulsion technology," said Barbara Chance, Director of Mobile Source Regulatory Compliance for Allison Transmission. "The H 40/50 EP legacy system was the first electric hybrid propulsion system to be certified in California for transit buses and coaches. We're honored to now collaborate with CARB to earn certification for the eGen Flex, which provides revolutionary capabilities for public transit." The Cummins B6.7 and L9 diesel-electric hybrid engines feature proven technology designed and developed in-house that is optimized to deliver the efficiency, durability and performance on which transit bus customers depend. The B6.7 diesel-electric hybrid engine is rated at 280 hp while the L9 diesel-electric hybrid engine is rated at 330 hp for the transit bus market. "Cummins is excited to have received the necessary CARB certifications for the integration of our engines into Allison's next generation electric hybrid propulsion system," said Francisco Lagunas, General Manager, North America Bus Business, Cummins Inc. "We believe the latest Cummins and Allison clean diesel power system will provide our bus customers an even more reliable and environmentally-friendly powertrain to help them be as successful as possible."

08:35 EDT Lightwave announces patent application to simplify polymer modulator fabrication - Lightwave Logic announced the publication of a U.S. patent application on a new invention that will simplify polymer modulator fabrication when integrated with silicon photonics for high-volume foundry manufacturing applications. This patent application, entitled "TFP optical transition device and method," illustrates the design of a simpler to fabricate, lower cost hybrid integrated photonics chip using electro-optic polymers which are more advantageous for high-volume production. The simplified fabrication approach enables us to simplify the production of very high speed, low power proprietary polymer modulators that will enable significantly faster data rates in the internet environment. The essence of the invention is a hybrid polymer-silicon photonics engine that fits into fiber optic transceivers that are used in the routers, servers and network equipment that are proliferating with the growth of data centers, cloud computing and optical communications capacity.

08:33 EDT Green Brick announces appointment of Manassa Murphy to its board of directors - Green Brick Partners announced that it has appointed Lila Manassa Murphy, CFA as a new independent director to the Green Brick Partners Board of Directors. Manassa Murphy will be filling a newly added seat on the GRBK Board. Since May 2021, Lila Manassa Murphy has served as EVP and Chief Financial Officer of Dundee Corporation, a public Canadian independent holding company.

08:33 EDT PSEG announces retirement of CEO Ralph Izzo and succession plan - PSEG announced that Ralph Izzo, chair, president and CEO, will retire from the company. His last day will be December 31. As part of a planned leadership succession process, the PSEG Board of Directors elected Ralph LaRossa, COO, as president and CEO effective September 1. Izzo will serve as executive chair of the board effective September 1 until his retirement. He will continue to lead the board and work closely with LaRossa in support of a smooth succession and continue his keen focus on energy policy matters. LaRossa will assume the additional responsibilities of chair on January 1, 2023. For over three decades, LaRossa's career at the company has enabled him to hold leadership roles overseeing all of the operating businesses of PSEG including: Public Service Electric & Gas, PSEG Power, PSEG Long Island, and PSEG Services functions including information technology, and cyber and physical security.

08:32 EDT Moderna says bivalent booster candidate neutralizing titers superior against VOC - Moderna announced new clinical data on its bivalent COVID-19 booster platform, including data on the company's first bivalent booster candidate, mRNA-1273.211, which includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants of concern including Omicron. A 50 B5g booster dose of mRNA-1273.211 demonstrated superiority against Beta, Delta and Omicron variants of concern, or VOC, one month after administration. Superiority continued six months after administration for Beta and Omicron variants of concern as well, the company announced. A 50 B5g booster dose of mRNA-1273.211 was generally well tolerated with a reactogenicity profile comparable to a booster dose of mRNA-1273 at the 50 B5g dose level, the company added. A booster dose of mRNA-1273.211 demonstrated superiority against the ancestral SARS-CoV-2 and the Beta, Delta and Omicron variants one month after the booster dose and superiority against the ancestral SARS-CoV-2, Beta and Omicron 6 months compared to the booster dose of mRNA-1273. There was a 2.20-fold and 2.15-fold increase in the neutralizing antibody titers against Omicron with the mRNA-1273.211 booster dose compared to the mRNA-1273 booster dose at 1 month and 6 months, respectively. The mRNA-1273.211 booster candidate was generally well tolerated in 300 study participants who received the 50 B5g dose and 595 participants who received the 100 B5g dose of mRNA-1273.211, out of 895 participants in total. "We are pleased with these data for our first bivalent booster candidate, mRNA-1273.211. We believe that these results validate our bivalent strategy, which we announced and began pursuing in February 2021. The results indicate that mRNA-1273.211 at the 50 B5g dose level induced higher antibody responses than the 50 B5g mRNA-1273 booster, even when additional variants of concern were not included in the booster vaccine. Our latest bivalent booster candidate, mRNA-1273.214, which combines the currently authorized Moderna COVID-19 booster with our Omicron-specific booster candidate, remains our lead candidate for the fall 2022 Northern Hemisphere booster. We look forward to sharing initial data on mRNA-1273.214 later in the second quarter. We believe that a bivalent booster vaccine, if authorized, would create a new tool as we continue to respond to emerging variants," said Stephane Bancel, CEO of Moderna.

08:31 EDT Sirius XM announces quarterly dividend of 2.1961c per share - Payable in cash on May 25 to stockholders of record at the close of business on May 6.

08:29 EDT Tracon Pharmaceuticals announces amended ENVASARC protocol - TRACON Pharmaceuticals announced that the amended ENVASARC protocol approved by the U.S. Food and Drug Administration, FDA, in February has now been approved by institutional review boards or ethics committees at all 30 clinical sites: 29 in the United States and one in the United Kingdom. In February, the FDA approved the amended ENVASARC protocol following the Independent Data Monitoring Committee, IDMC, recommendation based on the highly tolerable safety profile and the significantly higher objective response rate observed in lower weight patients in ENVASARC, to increase the dose of envafolimab to 600 mg every three weeks, which is double the original envafolimab dose of 300 mg Q3W. TRACON expects to report results of IDMC mandated interim safety reviews and the interim efficacy review in the second half of 2022. "We are pleased to have opened every site under the amended ENVASARC protocol that increases the envafolimab dose to 600 mg within two months of FDA approval in February," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "We look forward to the interim ENVASARC safety and efficacy data reviews by the IDMC in the second half of 2022."

08:28 EDT Aeterna Zentaris secures new European patent related to use of macimorelin - Aeterna Zentaris announced that European Patent Office, EPO, has issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin for use to diagnose growth hormone deficiency, GHD, in adults. Dr. Klaus Paulini, Chief Executive Officer of Aeterna, commented, "Patents are an important tool to protect our intellectual property and a critical step in bringing any new drug to market. So we are pleased to have such stronger protection around our innovative product Ghryvelin(TM)/ Macrilen(TM) in the EU, and several non-EU countries. There is also an opportunity to build greater protection by entering the patent in the national phase in 41 European countries, and we will move ahead with a plan to take advantage of this. This patent also provides protection for our licensing partner in Europe and the United Kingdom, Consilient Health, for the commercialization of macimorelin." The patent was issued pursuant to Article 97 of the EPC, with the number EP3729100. The new European patent covers the use of macimorelin to detect GHD in adults, with a base patent term extending until 2038. The EP3729100 patent claims exactly the label of the product approved by the European Commission in January 2019. The patent provides intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as UK and Turkey.

08:26 EDT Embraer delivers six commercial, eight executive jets in Q1 - Embraer delivered a total of 14 jets in the first quarter of 2022, of which six were commercial aircraft and eight were executive jets (six light and two large). As of March 31, the firm order backlog totaled $17.3B.

08:25 EDT Telus introduces Stream+ bundle - TELUS introduced Stream+, the first and only premium streaming bundle in Canada. Stream+ combines Netflix Premium plan, Apple TV+, and discovery+ on one single bill for $25 per month, and is available to new and existing TELUS Mobility customers. With Stream+, customers can enjoy their favourite shows and movies from the comfort of their home or while on-the-go, powered by TELUS' wireless network.

08:23 EDT Freeline appoints Schneider as Chief Financial Officer - Freeline Therapeutics announced that Paul Schneider has been appointed Chief Financial Officer, CFO, effective May 16, 2022, based in Boston. Schneider joins Freeline from Exo Therapeutics, where he served as Senior Vice President, Finance and Operations.

08:22 EDT Vislink, Hitachi Kokusai Electric Comark announce reseller agreement - Vislink has signed a partnership agreement with Hitachi Kokusai Electric Comark. This agreement appoints COMARK as an authorized reseller, integrator, and service provider of Vislink's high quality, reliable, real time video communication solutions for NextGenTV deployments. With this new agreement, COMARK and CDS will offer Vislink's ATSC 3.0 ready digital video microwave system: IPLink 3.0. This new system allows the broadcaster to migrate from the traditional ASI transport platform to a future IP-centric system architecture. "We are pleased to enter into this partnership with COMARK," said Mickey Miller, CEO of Vislink. "Their long heritage of innovation and deep relationships in the broadcast space make them the ideal partner for introducing our IP Link 3.0 system to the widest range of broadcasting organizations. We specifically designed IP Link to help contribute to the transformation from ATSC 1.0 to 3.0 by enabling immersive and interactive experiences for viewers, as well as opportunities for more efficient business models and avenues for monetization for broadcasters."

08:20 EDT Enzo Biochem announces New York State DOH approval of AMPIPROBE HPV test - Enzo Biochem announced that it has received approval from the New York State Department of Health, DOH, for its AMPIPROBE HPV test. The AMPIPROBE HPV test is Enzo's PCR-based test designed to detect 14 high-risk human papillomavirus variants. "We are very excited to have received approval for our HPV test from the New York State DOH, representing another important milestone in our continuing efforts to expand the menu of molecular diagnostics tests available on our GENFLEX platform," said Hamid Erfanian, Chief Executive Officer of Enzo. "We expect to make several other molecular LDT announcements this year and provide a timeline of FDA submissions for US regulatory approval of these tests. The approval process in New York is extremely thorough and requires the exhaustive review of the test's performance. The achievement of this high threshold leaves us well positioned for success as we pursue US and international regulatory approvals."

08:19 EDT Ocuphire Pharma appoints Pepose as CMA, announces upcoming presentations - Ocuphire Pharma announced the appointment of Jay Pepose, M.D., Ph.D., as its Chief Medical Advisor, CMA. In addition, Dr. Jay Pepose, Dr. Ralph Chu, and Dr. Marguerite McDonald will deliver three presentations on Nyxol at the American Society of Cataract and Refractive Surgery, ASCRS, which will be held in Washington, D.C. from April 22-26, 2022. Dr. Pepose has served on Ocuphire's Medical Advisory Board since 2018 and Board of Directors since 2021. A specialist in refractive surgery and corneal and external diseases, he is the founder and Medical Director of the Pepose Vision Institute. He also founded the Midwest Corneal Research Foundation, now the Lifelong Vision Foundation. Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma, said, "We are excited to share three podium presentations on positive efficacy data with Nyxol from our second Phase 3 trial, integrated safety data from the MIRA-2 and MIRA-3 registration trials, and positive single-agent Nyxol Phase 2 data at ASCRS. We are pleased to sponsor the ASCRS Beyond 20/20 educational series, which represents a great opportunity to connect with leading physicians and thought leaders."

08:17 EDT Ipsidy appoints Trelin to board of directors - authID.ai announced that Joe Trelin has been named to the company's Board of Directors. As the former Chief Platform Officer of CLEAR, Trelin brings to authID "invaluable industry expertise in technology product management as well as systems, platform, and application development," the company said. He is the Company's fifth independent director, bringing the total number of directors to eight executives from senior leadership roles spanning technology, IT consulting, operations, risk, accounting, and financial services.

08:15 EDT PDS Biotechnology receives $1.2M after selling NOL tax benefits - PDS Biotechnology announced that on April 18, 2022, the Company received $1.2M from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company's participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program for State Fiscal Year 2021.

08:13 EDT Super League introduces DreamWorks' The Bad Guys to the gaming metaverse - Super League Gaming announced the introduction of five characters from the new DreamWorks Animation feature film, The Bad Guys, into the gaming metaverse. DreamWorks Animation, a division of the Universal Filmed Entertainment Group within NBCUniversal, is Super League's first partner showcasing its recently launched innovative 3D ad units. The promotional campaign, designed to excite gaming communities around the film's unforgettable characters, leverages Super League's innovative 3D interactive ad units and international advertising network, which reaches more than 75mm young gamers monthly. . With this new campaign, The Bad Guys characters come to life in front of a player's eyes every time a player passes by. As they encounter pre-programmed dialogue boxes that trigger exciting and fun conversation, gamers can get to know and start bonding with the film's colorful characters prior to the film's April 22 release. In just the first four days of the program, the collection of ad units, including The Bad Guys billboards, animated GIFs, and 3D ads, generated more than 10 million impressions of at least 10 seconds in duration, and were seen by more than 2.2 million unique players. More significantly, players self-selected to interact with the 3D characters for more than 42 days of total chat time, yielding a 62% engagement rate.

08:11 EDT Freshworks announces 'Global Jam' 25 city world tour - Freshworks announces its 'Global Jam' - a two-month tour of events in 25 cities across five continents - to bring together leaders in customer experience, IT, sales, marketing and operations. The Freshworks Global Jam will run from May 3 through June 16, starting in San Francisco and ending in London featuring customers like Allbirds, Cityscoot, Internetstores, Oatly, SWVL, Zalora, Zoom US and more.

08:10 EDT Splash Beverage appoints Ron Wall as CFO - Splash Beverage Group announced the appointment of Ron Wall as CFO effective May 2nd. Most recently, from 2009 until present, Wall was CFO for William Grant & Sons, an independent family-owned, distiller of Scotch Whiskey and other spirts selling to more than 200 markets in 50 global locations. His responsibilities at Splash will include overseeing all financial aspects of the company including accounting, tax, financial planning and analysis, treasury, M&A activities and capital markets. He will report to the company's CEO Robert Nistico.

08:09 EDT IonQ and Hyundai Motor expand partnership to use quantum computing - IonQ and Hyundai Motor Company announced a new project designed to apply quantum machine learning to image classification and 3D object detection for future mobilities. Using a breakthrough in encoding images into quantum states, IonQ is already well underway in classifying 43 types of road signs using IonQ's quantum processors. The next phase will see the two companies apply IonQ's machine learning data to Hyundai's test environment and simulate various real-world scenarios. "We are excited to expand our existing relationship with Hyundai Motor to focus on another key aspect of next-generation mobility," said Peter Chapman, President and CEO of IonQ. "From partnering on battery research for electric vehicles to image classification and object detection research for automated driving, we expect to see quantum computers become an even more integral part in developing novel transportation solutions." As part of this project, IonQ and Hyundai will look to develop quantum techniques for the broad task of 3D object detection, expanding the current work on recognizing road signs to include other objects like pedestrians or cyclists. Running object recognition tasks on IonQ's latest quantum computer, IonQ Aria, should enable more efficient processing with lower costs, leading to the development of safer, more intelligent mobilities in the future. With 20 algorithmic qubits IonQ Aria is the industry's most powerful quantum computer based on standard application-oriented industry benchmarks.

08:08 EDT Secoo announces changes to board composition - Secoo (SECO) announced that its Board of Directors has approved the appointment of Shun Lam Tang as a director to the Board and the resignation of Dr. Jun Wang from the Board, both effective April 19, 2022. Shun Lam Tang has served as an independent director of Missfresh (MF) since August 2021, as well as an independent director of 58 Freight since October 2021.

08:07 EDT Eyenovia presents at American Sociey of Cataract and Refractive Surgery meeting - Eyenovia announced that the Company will present an ePoster at the American Society of Cataract and Refractive Surgery Annual Meeting, which is being held April 23-26 in Washington, D.C. Poster Title: Evaluation of Two Mydriatic Dosing Regimens Delivered by MICRO-Array Print Technology for Comparison of Pupil Dilation SPEED. Summary: This study demonstrated the speed to clinically meaningful dilation from a single spray of Microdose Array Print Dispenser administered tropicamide-phenylephrine fixed combination solution. The study results showed that almost three out of four patients reached clinically meaningful dilation by 15 minutes. The MAP technology facilitated accurate and efficient topical ocular administration with 98% of doses successfully administered on first attempt. There were no ocular or systemic adverse events reported. Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief Medical Officer of Eyenovia, commented, "The results of the SPEED study demonstrated that pupil dilation with our proprietary Optejet dispensing technology is both quick and effective, with drug levels substantially less than could be achieved using traditional eye droppers. This confers many benefits to both ophthalmologists and their patients, the latter being exposed to far less drug and preservatives with Optejet, which can lead to side effects and long-term ocular stress.

08:05 EDT Gesher I Acquisition receives additional capital commitment - Gesher I Acquisition Corp. announced that Composite Analysis Group, an affiliate of Safer Logistics, LLC, has agreed to provide Gesher $10M of committed capital to backstop redemptions by shareholders of Gesher in connection with Gesher's initial business combination if certain minimum cash conditions are not met. This is the second backstop commitment Gesher has obtained. In exchange for the Backstop Commitment, at the closing of an initial business combination, the company has agreed to issue and sell to Composite 1M ordinary shares at a purchase price of $10 per share and 100,000 warrants, subject to the terms and conditions of the backstop agreement.

08:05 EDT Prologis reports Q1 Cash Same Store NOI 8.7%

08:04 EDT Enphase Energy expands agreement with ADT Solar - Enphase Energy and ADT Solar, formerly Sunpro Solar, announced that ADT Solar is now exclusively offering Enphase IQ8 Microinverters as part of its comprehensive home energy solution. This announcement follows ADT Solar and Enphase Energy's recent expansion agreement to include Enphase IQ Batteries. "We are pleased to see industry leaders like ADT Solar moving to exclusively offer IQ8," said Dave Ranhoff, chief commercial officer at Enphase. "ADT Solar and Enphase Energy have maintained a great alliance for years while providing a high level of quality and customer service. Together, we are pleased to offer an innovative and differentiated home solar and battery solution, helping customers reach higher levels of energy independence while saving money on their energy bills."

08:03 EDT Singing Machine launches new line of karaoke products - The Singing Machine Company announced it is launching a new line of karaoke products in partnership with a major national U.S. retailer. The Company is introducing proprietary new SingCast technology which allows customers to wirelessly cast high-definition karaoke videos from a mobile device to the karaoke machine to display the lyrics on a connected TV. The SingCast technology is specifically designed to integrate with the Company's iOS and Android Apps for access to its digital subscription karaoke content catalog. Starting this spring 2022, these new products will be available for sale at the retailer, in its flagship consumer electronics department, and will be available nationwide.

08:01 EDT Clarus announces upsized $425M credit agreement - Clarus Corporation announced that it has amended and upsized its existing senior secured credit facility jointly led by JPMorgan Chase Bank, N.A. and Bank of America, N.A. with U.S. Bank National Association, Regions Bank, Wells Fargo Bank National Association, Texas Capital Bank National Association and Zions Bank participating in the lender group. Under the terms of the upsized credit agreement, Clarus has access to an increased revolving credit facility of $300 million and a $125 million term loan. The facility also includes an uncommitted accordion feature of $175 million, for a total borrowing capacity of up to $600 million. The revolving credit facility also allows for borrowings in certain foreign currencies. Generally, for U.S. dollar borrowings under the credit facility, the applicable interest rate will be based on either an adjusted SOFR rate or an alternative base rate, plus an applicable margin ranging from 1.5 percent to 2.625 percent per annum. The amended credit facility matures in April 2027. The term loan was fully borrowed at the closing of the facility and cannot be reborrowed.

07:44 EDT Immuron announces request for funding has been considered by METC - Immuron announces that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body 'Medical Technology Enterprise Consortium,' METC. Immuron is pursuing a regulatory pathway to license Travelan with the Food and Drug Administration via a Biologics License Application. The proposed indication is to reduce the risk of contracting travelers' diarrhea caused by bacterial pathogens. The Company was recently awarded $3.43M by MTEC for the development of a Travelan dosing regimen acceptable for use by the US military. In this new MTEC request for funding, Immuron is seeking an additional $4M to fund the Investigational New Drug Application, CMC Assay Development and Validation, Nonclinical Safety Studies and Stability Studies required to support the BLA. Immuron was formally notified that no government funding is immediately available, however, this application has been deemed 'eligible for funding' and will be eligible for award for a period of up to two years. The Company is also pleased to announce that work on the Investigational New Drug application to evaluate the efficacy of a single dose regimen of Travelan in a controlled human infection model clinical study using the enterotoxigenic Escherichia coli strain H10407 is progressing well.

07:42 EDT Macellum and Ancora send letter to SpartanNash holders on real-estate holdings - Macellum Advisors and Ancora Holdings Group, which beneficially own approximately 4.5% of the outstanding common shares of SpartanNash announced they have filed their definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to the Company's shareholders. The Investor Group has nominated three highly qualified and independent candidates for election to SpartanNash's Board of Directors The Investor Group's letter to fellow shareholders can be viewed here. Jonathan Duskin, Managing Partner of Macellum Capital Management, LLC, and Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora Holdings Group, LLC, issued the below statement: "Our robust analysis and engagement have led us to believe SpartanNash's leadership is wed to a flawed corporate structure and has failed to implement basic operating initiatives while leaving $1B of owned real estate sitting idle on the balance sheet, resulting in unjustifiably poor long-term operating and financial results. We contend the blame falls squarely on the SpartanNash Board and its long-tenured members, who have presided over numerous strategic missteps, significant c-suite turnover and the lack of a clear and credible operating strategy. In our view, SpartanNash is at a critical inflection point following years of operational and share price underperformance, lagging revenue and sales growth, poor capital allocation decisions and a long history of failed acquisitions under the incumbent Board. We believe many credible suitors are interested in acquiring SpartanNash. At a time when major grocery and food distribution players are embarking on their own strategic review processes, SpartanNash should immediately explore all paths to value creation before this round of consolidation ends. In light of these numerous concerns, we contend shareholder-driven change is urgently needed in the boardroom. We believe a properly refreshed Board, equipped with our highly qualified nominees, can oversee the development of a credible operating plan and objectively weigh it against available strategic alternatives to determine the best avenue toward shareholder value creation. Our slate - which includes Jonathan Duskin, John E. Fleming and Michael J. Lewis - has the right mix of corporate governance experience, finance acumen, grocery and food distribution expertise, strategic planning knowhow and sorely needed ownership perspectives to ensure the Company finally has an effective, transparent plan for delivering enhanced value. We look forward to giving shareholders the opportunity to vote for a better path forward for SpartanNash at this year's Annual Meeting."

07:40 EDT Vitalhub announces multi-year licensing deal with Royal Orthopaedic Hospital - VitalHub announces a multi-year licensing agreement of subsidiary Intouch With Health's digital, at-home pre-op solutions, Synopsis Home and Synopsis iQ, to the Royal Orthopaedic Hospital NHS Foundation Trust. The Royal Orthopaedic Hospital NHS Foundation Trust is a new customer of the Company, having signed a multi-year licensing agreement to access the Company's Synopsis Home and Synopsis iQ products. "We are excited to engage in this new partnership with Royal Orthopaedic Hospital NHS Trust," said Dan Matlow, CEO of VitalHub Corp. "This deal provides further evidence of the market traction of our award-winning Synopsis products, and the ongoing demand for our offerings. We look forward to continuing to support our customers as we advance our growth strategy."

07:38 EDT Checkmate Pharmaceuticals Inc trading resumes

07:38 EDT American Campus trading halted, news pending

07:38 EDT HCW Biologics CEO to be featured speaker at CEB-2022 - HCW Biologics announced that Hing Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology taking place in Boston, Massachusetts on April 18-20, 2022. Dr. Wong's presentation entitled, "Bifunctional Immunotherapeutic HCW9218 for Cancer and Inflammaging," will highlight preclinical data from in vivo animal studies demonstrating the ability of the Company's lead investigational candidate, HCW9218, to both enhance the anti-tumor efficacy of chemotherapy drugs and diminish their harmful side effects by reducing therapy-induced senescence and eliminating TGF-beta and its immunosuppressive effects. The presentation will highlight information contained in a pivotal paper recently published in a peer-reviewed journal entitled, "Immunotherapeutic HCW9218 Augments Anti-tumor Activity of Chemotherapy via NK Cell Mediated Reduction of Therapy Induced Senescent Cells." Chaturvedi P., et al., Molecular Therapy, 2022; 30:1171-1187. Dr. Wong will also share for the first time preclinical data showing that HCW9218 is a promising senolytic and senomorphic agent for age-related pathologies. Dr. Wong stated, "Chemotherapies seed cancer relapses and metastases, and trigger inflammation-based side effects in treated patients by inducing cancer senescent cells and normal tissue cellular senescence. We have previously demonstrated, in preclinical studies, that HCW9218 can effectively reduce therapy-induced cancer and normal tissue cellular senescence to augment the anti-tumor activities of chemotherapies and alleviate their side effects. Thus, we believe HCW9218 can make chemotherapy cancer treatments work better with fewer side effects and extend the health span for cancer survivors. Now, we discovered that HCW9218 can also reduce accumulated senescent cells due to the naturally aging process or metabolic dysfunction leading to the improvement of heath span of experimental animals. I am thrilled to share this transformative discovery with the scientific community at the CEB-2022 conference." In explaining why he selected CEB-2022 as the venue to feature HCW Biologics' work on anti-inflammaging, Dr. Wong stated, "CEB-2022 is a gathering of scientific experts from around the world who come together to discuss innovation and advancement in the fields of cell and molecular biology. HCW Biologics is developing immunotherapeutics that do not treat a single indication or symptom. Our approach is to treat a patient systemically to remove the underlying problems causing the condition. The conference provides an audience who will be able to appreciate what we believe is a novel approach backed by breakthrough data." HCW9218 will soon reach the clinical development stage for cancer. The Company expects to gain human data from two clinical trials that will guide the future development of HCW9218 for other age-related pathologies.

07:37 EDT Natera announces results from Renasight study - Natera announced the results of a large, real-world study demonstrating a high yield rate for positive genetic findings with its Renasight test in patients with chronic kidney disease, or CKD. The study, published in the American Journal of Nephrology, reports on renal genetic testing results using Renasight to test for 382 genes associated with CKD on 1,007 unique patient samples that were ordered by general and transplant nephrologists for clinical purposes. Positive genetic findings were identified in 21.1% of cases, with a total of 220 positive results identified across 48 genes. In addition, the results also identified individuals with positive findings in more than one gene. The study concludes that Renasight, "is highly effective in identifying monogenic variants underlying inherited kidney diseases and has utility for genetic diagnoses in the nephrology setting."

07:35 EDT Quipt Home Medical acquires Good Night Medical for $7M in cash - Quipt Home Medical announced that it has acquired Good Night Medical, a business with operations across seven U.S. states, reporting unaudited trailing 12-month annual revenues of approximately $7.5M and with anticipated Adjusted EBITDA of $1.5M post integration. The acquisition encompasses locations across seven U.S. states including Arkansas, Georgia, Massachusetts, North Carolina, Ohio, Texas and California. The acquisition provides Quipt an expansionary opportunity into Massachusetts, North Carolina and Texas, which are new U.S. states for Quipt's coverage sphere including important new commercial insurance contracts. The other four U.S. states are current areas of service for Quipt, which provide for actionable revenue and cost synergy opportunities as further scale is created in each operating region. The expansionary operating footprint aligns closely with regions that have a high prevalence of Chronic Obstructive Pulmonary Disease, a key target patient group; cumulatively the seven states Good Night Medical operates in contain some of the highest prevalence U.S. states. According to the National Institutes of Healt, about 5 million people between the seven states have COPD1. The favorable demographics, additional insurance contracts, and infrastructure provides Quipt with the right set of circumstances to further accelerate its national expansion efforts as a leader in clinical respiratory care. The integration process will include Quipt applying its proven subscription-based resupply program to each acquired business unit, as well as the highly intensive service model Quipt is known for. Consistent with the transactions Quipt has completed to date, Good Night Medical brings an experienced operational team. Good Night Medical has been a leader in the respiratory home care services space for over 9 years and has several difficult to obtain insurance contracts that significantly enhance Quipt's presence in each of Good Night Medical's regions. Good Night Medical has 10,000 active patients, bringing Quipt's total to approximately 180,000 active patients, and like Quipt, Good Night Medical offers high-quality service, equipment, and supplies. Moreover, Good Night Medical has strong diversification amongst referral sources, and a payor base, with exposure to less than 30% from Medicare. Furthermore, Good Night Medical has no exposure to ventilation therapy, which provides Quipt an opportunity to grow as well as other complimentary clinical respiratory products and services. In addition, Good Night Medical provides Quipt the opportunity to add patients to Quipt's existing subscription-based resupply program, and Quipt expects that it can derive strong revenue synergies from this initiative. Under the terms of the definitive purchase agreement, Quipt acquired Good Night Medical for approximately $7M in cash. It is expected the acquisition will increase Quipt's annual revenues by approximately $7.5M, and, post integration, Adjusted EBITDA by $1.5M.

07:35 EDT Sono Motors provides FY21 corporate update - Sono Motors announced the following updates for FY21: Several B2B Projects for Solar Integration Delivered, Including Solar Buses for Public Transport in Q1 2022, Last Mile Delivery Truck and US RV Retailer in 2021; between 2021 and Q1 2022 Sono Solar B2B Partner Arrangements Increased From 2 to 17; Signed a Contract Manufacturer With Years of Experience in Production for Premium OEMs, Which Will Provide Production Capacity for 257,000 Cars Within 7 Years; As of 31 March 2022, Reservations for The Sion Solar Electric Vehicle Totaled Over 17,000; Development of the Sion Progressed as Planned With Building of a Series-Validation Vehicle Fleet, to Be Presented to the Public This Summer; and Sono Car Sharing App Launched in Germany. "We have achieved major milestones on our growth path. We're scaling up our Sono Solar business, have delivered several products to B2B customers in the last months, and thus generated first revenues. Our proprietary solar technology is already contributing to climate protection and the reduction of CO2 emissions on Munich public transport and supporting the city's clean air targets. These examples showcase our plan to diversify our business by establishing our B2B solar business as a strategic pillar, equal to our solar electric vehicle, the Sion," states Laurin Hahn, CEO and co-founder of Sono Motors. "This year we also have a clear focus on enhancing the quality, testing, and speed of the Sion program. We are now well into the series-validation phase and progressing with vehicle testing and certification. Our collaborative working with our new contract manufacturer positions us well to keep our promise and deliver a climate-neutral Sion to our customers next year," Hahn adds.

07:34 EDT Lockheed Martin backs FY22 cash from operations greater than, equal to $7.9B - Backs FY22 free cash flow greater than, equal to $6B.

07:32 EDT Kalera secures $30M credit facility - Kalera announced that it has secured a ten-year, $30 million Senior Secured Credit Facility with Farm Credit of Central Florida to support capital expenditures and working capital needs of the Company across the entire United States. The credit facility was entered into by Kalera Inc. a United States based wholly owned subsidiary of Kalera AS. The Credit Agreement has a term of 120 months and includes standard terms and conditions customary in secured financing transactions of this nature.

07:31 EDT Parts iD adds over 5,000 tire installation locations - PARTS iD announced that it added over 5,000 new locations to its tire installation network during the first quarter of 2022, bringing the total number of participating installers to 7,270. When browsing CARiD.com's broad inventory of tires, customers across the 48 contiguous U.S. states and Washington, DC now have direct access to more local installation partners who can complete the job. With this expansion, PARTS iD reports an increase in installer density and service coverage in highly populous states and metropolitan areas including Texas, metro New York, Southern California, Florida and Chicago. Similarly, new installation locations are now available in less populated states and regions that previously saw low or no coverage through the tire installation network including Iowa, West Virginia, Vermont, Montana and North Dakota.

07:17 EDT Microbix Biosystems to present respiratory virus controls data at two events - Microbix Biosystems announces it will be presenting performance results of its quality assessment products, QAPs, that support molecular-diagnostic, MDx, screening-tests for respiratory viruses at two industry congresses - "Labquality Days" in Helsinki, Finland April 20-21, 2022 and "ECCMID 2022" in Lisbon, Portugal, April 23-26, 2022. Labquality Days is an annual international congress focusing on quality in laboratory medicine and medical devices. It is sponsored by Labquality Oy. ECCMID 2022 is the 32nd annual congress organized by the European Society of Clinical Microbiology and Infectious Diseases. At these events Microbix will be presenting performance results of its QAPs for support of MDx tests that detect multiple respiratory viruses from a single patient-sample. At Labquality Days, Microbix's presentation is titled "Microbix's Cross-Platform Compatible Respiratory Virus Multiplex Samples for use as a Quality Management Tool in Laboratory Syndromic Testing." At ECCMID, Microbix's presentation is titled "Respiratory Virus Multiplex Formulations Desiccated on Copan's FLOQSwab for use as Cross-Platform Compatible EQA Samples and Laboratory Quality Controls." The two poster presentations detail the performance of three Microbix "multiplex" QAPs that each support testing for three to four pathogens, collectively providing quality management support of testing for 11 common respiratory viruses.

07:14 EDT Enthusiast Gaming announces return of Pocket Gamer Connects in Seattle - Enthusiast Gaming will host its next live event under its Pocket Gamer Connects, PGC, brand in Seattle, Washington from May 9-10. PGC Seattle 2022 attendees can learn and meet with hundreds of companies in the gaming space from indie developers, publishers, media, investors, and everything in between. More than 120 industry speakers across 17 themed tracks will share insight and knowledge on a wide variety of topics. "We are thrilled to once again be hosting live events. Pocket Gamer Connects continues to push new boundaries and create a unique experience for attendees, speakers, and sponsors. As we get set to return to Seattle, it's great to see the depth of topics being discussed, including how blockchain, metaverse, and NFT's are impacting the evolution of the games industry," said Adrian Montgomery, CEO of Enthusiast Gaming.

07:12 EDT Else Nutrition releases plant-based Else Super Cereal for babies - Else Nutrition announced the release of its plant-based Else Super Cereal for babies, furthering the brand's mission to provide families with sustainable, dairy-free alternatives of complete nutrition products for toddlers and kids. Else Super Cereal is the first and only baby cereal line in the U.S. granted the Clean Label Project Purity Award. "We've heard the resounding need and demand from parents and pediatricians for a clean label baby cereal," said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. "For many babies, the introduction of baby cereal is their first exposure to foods other than breast milk or infant formula, underscoring the importance of pure and clean options packed with nutrition. The launch of Else Super Cereal reinforces our mission to lead the clean, healthy revolution for babies and children. Else is building a portfolio of nutrition products that meets feeding needs starting as early as infancy," she added.

07:09 EDT Lizhi collaborates with Xiaomi platform to launch product in Leapmotor EVs - LIZHI (LIZI) announced that it is collaborating with the in-car Xiaomi (XIACF) Quick App Platform to integrate LIZHI's in-car audio product into Leapmotor vehicles' operating system. Leapmotor is a smart electric vehicle, EV, automaker based in China. This partnership marks Leapmotor as the first smart car company to integrate LIZHI's in-car audio product through the Xiaomi Quick App Platform. Through this partnership with the Xiaomi Quick App Platform, LIZHI brings podcast content and audio experiences to a broader user demographic and satisfies users' varied in-car entertainment demands through the Company's in-house suite of technologies. Jinnan Lai, Founder and CEO of LIZHI, said, "We are very pleased to collaborate with the in-car Xiaomi Quick App Platform to bring an expansive library of audio content to even more users. We will also continue to cooperate with Internet of Vehicles (IoV) platforms to provide a wider user base with high-quality, diverse, and customized in-car audio experiences and further implement LIZHI's in-car audio initiatives."

07:08 EDT SVB Financial to rebrand its four primary businesses under SVB - SVB Financial Group announced a rebrand of its four primary businesses the brand name SVB. The four primary businesses are Silicon Valley Bank, SVB Capital, SVB Private and SVB Securities. "Over the past several years, SVB has invested heavily in our business to build a comprehensive financial services platform to help our clients achieve their goals," said Greg Becker, President and CEO of SVB. "We have evolved far beyond our roots as a commercial bank for startups. As we approach our 40th year in business, we are using the brand "SVB" to better reflect the full power of our suite of services across our four complementary businesses."

07:07 EDT BioXcel Therapeutics announces formation of OnkosXcel Therapeutics - BioXcel Therapeutics announced the formation of wholly-owned subsidiary OnkosXcel Therapeutics to develop transformative medicines in oncology. OnkosXcel is focused on the sustained expansion and optimization of the oncology franchise, while providing maximum strategic and financial flexibility. OnkosXcel plans to progress the development of BXCL701, an investigational orally administered innate immune activator designed to initiate inflammation in the tumor microenvironment. BXCL701 is being evaluated in combination with KEYTRUDA in an ongoing Phase 2 trial in metastatic castration-resistant prostate cancer patients with either adenocarcinoma or small cell neuroendocrine carcinoma phenotype. Most recently, the Company announced positive efficacy and safety data at the 2022 ASCO Genitourinary Cancers Symposium, reinforcing the broad potential of BXCL701 to extend the activity of checkpoint inhibitor therapy into "cold" tumor settings. BXCL701 is also being evaluated in combination with KEYTRUDA in advanced, "hot" and CPI-resistant tumors in an investigator-initiated, Phase 2 study led by MD Anderson Cancer Center, with additional efficacy data expected in the second half of 2022. BioXcel Therapeutics believes BXCL701 is one of the most advanced orally available, innate immune activators in the clinic and it has been evaluated in approximately 800 healthy subjects and cancer patients. OnkosXcel plans to explore the BXCL701 clinical development program in hematological malignancies and other solid tumors. The Company plans to provide additional details regarding OnkosXcel in the second half of 2022.

07:05 EDT BioXcel Therapeutics announces $260M strategic financing agreements - BioXcel Therapeutics announced strategic financing agreements with funds managed by Oaktree Capital Management, and Qatar Investment Authority, QIA. Under the agreements, Oaktree and QIA will provide up to $260M in gross funding to support the Company's commercial activities of IGALMI sublingual film. In addition, the financing is intended to support the expansion of clinical development efforts of BXCL501, which includes a pivotal Phase 3 program for the acute treatment of agitation in patients with Alzheimer's Disease, and for the Company's additional neuroscience and immuno-oncology clinical programs. The long-term strategic financing process was led by Oaktree and is comprised of the following components: Credit Agreement: Up to $135 million in a delayed draw term loan; Revenue Interest Financing Agreement: Up to $120 million in a capped revenue interest on net sales of IGALMI and any other future BXCL501 products; Equity Investment: Up to $5 million purchase of BioXcel Therapeutics common stock. Under the agreement, BioXcel Therapeutics will receive $100M in the first tranches of the strategic financing following approval by the U.S. Food and Drug Administration of a New Drug Application in respect of the use of the Company's BXCL501 product for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. This condition was satisfied on April 5, 2022 with the FDA's approval of IGALMI. Upon closing of this transaction, and together with the Company's cash balance and anticipated business plan, BioXcel Therapeutics is expected to have a substantial multi-year working capital runway. Full execution of this financing would result in cash runway into 2025 for the Company.

07:03 EDT Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash - Regeneron Pharmaceuticals (REGN) and Checkmate Pharmaceuticals (CMPI) announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. The proposed acquisition values Checkmate at a total equity value of approximately $250M. Checkmate's lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 agonist delivered in a virus-like particle. The merger agreement provides for Regeneron, through a subsidiary, to initiate a tender offer to acquire all outstanding shares of Checkmate at an all-cash price of $10.50 per share of Checkmate common stock. The closing of the tender offer will be subject to certain conditions, including the tender of at least a majority of the outstanding shares of Checkmate common stock, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. Upon the successful completion of the tender offer, Regeneron will acquire all shares not acquired in the tender through a second-step merger. The transaction is expected to close in mid-2022.

07:02 EDT Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash

07:01 EDT Regeneron to acquire Checkmate Pharmaceuticals for $10.50 per share in cash

06:58 EDT Travelers reports Q1 book value per share of $106.40 - Down 5% from March 31, 2021; adjusted book value per share of $112.19, up 11% from March 31, 2021. Reports Q1 consolidated combined ratio of 91.3% and underlying combined ratio of 91.2%.

06:55 EDT Halliburton records Q1 pre-tax charge of $22M from write down of Ukraine assets - Halliburton recorded a pre-tax charge of $22M in the first quarter of 2022 primarily related to the write down of all its assets in Ukraine, including $16M in receivables, due to the ongoing conflict. This charge was included in "Impairments and other charges" on the company's condensed consolidated statement of operations for the three months ended March 31, 2022.

06:51 EDT Eagle announces settlement agreement with Hospira - Eagle Pharmaceuticals announced that it has reached a settlement agreement with Hospira. Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application, or NDA, referencing BENDEKA. The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances.

06:46 EDT Booz Allen makes investment in Reveal Technology - Booz Allen Hamilton announced it made a strategic investment in Reveal Technology, a visual analytics and edge artificial intelligence, or AI, company. Reveal delivers intuitive, rapid intelligence at the austere tactical edge where power, compute, and bandwidth are often in short supply. The company's Farsight software platform provides special operators and squads in high-risk environments with actionable intelligence, surveillance and reconnaissance, or ISR, capabilities at the unit level.

06:36 EDT SpringsWorks announces agreeement with Regeneron for nirogacestat - SpringWorks Therapeutics announced that the company has entered into a clinical trial collaboration and supply agreement with Regeneron Pharmaceuticals, to evaluate nirogacestat, SpringWorks' investigational gamma secretase inhibitor, in combination with Regeneron's investigational bispecific antibody targeting B-cell maturation antigen, or BCMA, and CD3, REGN5458, in patients with relapsed or refractory multiple myeloma. Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the surface of myeloma cells. In preclinical models, nirogacestat has been shown to increase levels of membrane-bound BCMA and reduce levels of soluble BCMA, thereby helping to enhance the activity of BCMA-targeted therapies, including CD3 bispecific antibodies. Under the terms of the agreement, Regeneron is responsible for the clinical development and will assume all costs associated with the study, other than expenses related to the manufacturing and supply of nirogacestat and certain expenses related to intellectual property rights.

06:34 EDT GlaxoSmithKline reports FDA accepts New Drug Application for daprodustat - GlaxoSmithKline announced that the U.S. Food and Drug Administration accepted the New Drug Application, or NDA, for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, for the potential treatment of patients with anaemia of chronic kidney disease, or CKD. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 1, 2023. Daprodustat is currently approved in Japan as Duvroq for patients with renal anaemia. In March 2022, the European Medicines Agency validated the marketing authorization application for daprodustat, which is currently under review. Additional regulatory filings are anticipated to continue throughout 2022.

06:31 EDT Hasbro to resume share repurchase program - "Our first quarter results were in line with our plans, as the team continued to manage supply chain disruptions, positioning us to meet or exceed our outlook for the year," said Deborah Thomas, Hasbro chief financial officer. "As we discussed at year end, pricing increases went into effect in our consumer products business at the beginning of the second quarter and will help offset the higher input and freight costs in future quarters. Given our cash position and positive outlook, we are resuming our share repurchase program with a plan to repurchase $75 to $150 million this year and remain on target to reach our gross debt to adjusted EBITDA target of 2.0 to 2.5X during 2023."

06:20 EDT AstraZeneca's Enhertu granted FDA Priority Review in U.S. in NSCLC patients - AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application of Enhertu for the treatment of adult patients in the US with unresectable or metastatic non-small cell lung cancer, or NSCLC, whose tumours have a HER2 mutation and who have received a prior systemic therapy. The application has also been granted Priority Review. Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo. Reference Link

06:07 EDT Microvast appoints Craig Webster as CFO - Microvast announced that Craig Webster, a long-standing member of the company's board of directors has been appointed as the company's new CFO, effective as of April 14. Yanzhuan Zheng, who has served as the company's CFO since 2010, will continue to serve as a member of the board and will transition into a senior advisory role with the company. Additionally, Microvast announced that Sascha Rene Kelterborn, the company's chief revenue officer and managing director of its Europe, Middle East and Africa division, has been appointed as president of Microvast, where he will lead the day-to-day operations of the company.

06:05 EDT Radware and Entelar sign a reseller agreement - Radware and Entelar announced that they have signed a reseller agreement. As part of the agreement, Entelar is expanding its vendor offerings to include Radware's application and network security solutions. Entelar, a New Zealand-owned IT distributor and subsidiary of Spark NZ Trading Limited, has its roots in aftermarket services and reverse logistics in the information and communications technology, or ICT, space.

06:04 EDT AppTech Payments to purchase Hothand - AppTech Payments announced its definitive agreement to purchase Hothand, a patent holding company which owns the intellectual property rights to a wide array of mobile credit/debit transaction and mobile search, location, offer, and payment fields. AppTech will acquire Hothand's portfolio of twelve patents focused on the delivery, purchase, or request of any products or services within a specific geolocation and time provided by a consumer from any cell phone anywhere in the U.S. The purchase price is a combination of cash and stock.

05:22 EDT Takeda Pharmaceutical receives approval from Japan MHLW for Nuvaxovid - Takeda announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare, or MHLW, for Nuvaxovid Intramuscular Injection. a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari. Takeda will begin distribution of Nuvaxovid doses purchased by the Government of Japan as soon as possible.

05:16 EDT Stellantis suspends production in Russia - The company said, "Given the rapid daily increase in cross sanctions and logistical difficulties, Stellantis has suspended its manufacturing operations in Kaluga to ensure full compliance with all cross sanctions and to protect its employees. Stellantis condemns violence and supports all actions capable of restoring peace."